{"id":"W2947105388","doi":"10.1200/jco.2019.37.15_suppl.1013","title":"Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Cohort; Oncology; Breast cancer; Tolerability; Phases of clinical research; Paclitaxel; Cancer; Gastroenterology; Adverse effect; Toxicity; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00110254,0.001446411,0.001486257,0.000447553,0.0004112859,0.001173329,0.0009859998,0.001219767,0.00398364],"category_scores_gemma":[0.0007934474,0.000606627,0.001522753,0.0003754238,0.0009345355,0.0008453642,0.0006218265,0.003741375,0.0008698659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001409333,"about_ca_system_score_gemma":0.001959535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002339078,"about_ca_topic_score_gemma":0.01107346,"domain_scores_codex":[0.999744,0.0001026668,0.000009987808,0.00005669995,0.00003970665,0.00004693952],"domain_scores_gemma":[0.9993829,0.0000608111,0.0001499763,0.00005028486,0.00003286437,0.0003231463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7886892,0.06283471,0.01027243,0.001346351,0.001919914,0.0005001594,0.0004257319,0.00307591,0.05464259,0.0006960977,0.01204341,0.06355352],"study_design_scores_gemma":[0.7456312,0.2278136,0.01453155,0.00005280826,0.0007822635,0.0006413881,0.00008758242,0.001327638,0.003103272,0.0002510156,0.005731525,0.00004609375],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827655,0.002023152,0.0005926465,0.0009101536,0.0001527205,0.007001188,0.003029173,0.0001104692,0.003414997],"genre_scores_gemma":[0.9719625,0.002936885,0.003573974,0.002041815,0.0002436527,0.006623759,0.006598177,0.00006518909,0.005953909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00398364,"threshold_uncertainty_score":0.01332664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1101164755050476,"score_gpt":0.505768883853412,"score_spread":0.3956524083483645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}